• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRBP alert in real time by email
    SC 13G/A 1 p24-3154sc13ga.htm CORBUS PHARMACEUTICALS HOLDINGS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Corbus Pharmaceuticals Holdings, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    21833P301

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

     

     

    CUSIP No. 21833P30113G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 21833P30113G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 21833P30113G/APage 4 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 21833P30113G/APage 5 of 7 Pages

     

     

    Item 1(a). Name of Issuer.
      Corbus Pharmaceuticals Holdings, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.
      500 River Ridge Drive, Norwood, MA 02062.

     

    Item 2(a). Name of Person Filing.
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.0001 per share (“Shares”), of the Issuer that were held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares that were held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares that were beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.0001 per share.

     

    Item 2(e). CUSIP Number.
      21833P301

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

    Item 4. Ownership.
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the close of business on September 30, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].
       

     

     

    CUSIP No. 21833P30113G/APage 6 of 7 Pages

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

     

    CUSIP No. 21833P30113G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  November 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:

    /s/ Jason M. Colombo

      Name: Jason M. Colombo
      Title: Authorized Person
       
       
      POINT72 CAPITAL ADVISORS, INC.
       
      By:

    /s/ Jason M. Colombo

      Name: Jason M. Colombo
      Title: Authorized Person
       
       
      STEVEN A. COHEN
       
      By:

    /s/ Jason M. Colombo

      Name: Jason M. Colombo
      Title: Authorized Person
       

     

    Get the next $CRBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRBP

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform
    William Blair
    12/2/2024Overweight
    Piper Sandler
    7/30/2024$85.00Outperform
    Wedbush
    7/22/2024$80.00Buy
    H.C. Wainwright
    6/26/2024$85.00Buy
    B. Riley Securities
    6/3/2024$60.00 → $80.00Outperform
    Oppenheimer
    5/13/2024$77.00Outperform
    RBC Capital Mkts
    3/6/2024$4.00 → $46.00Hold → Buy
    Jefferies
    More analyst ratings

    $CRBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Hodgson Ian claimed ownership of 25,977 shares (SEC Form 3)

      3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/18/25 4:45:04 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Smethurst Dominic sold $43,330 worth of shares (6,393 units at $6.78), decreasing direct ownership by 8% to 70,807 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/7/25 4:30:08 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Moran Sean F. sold $24,446 worth of shares (2,792 units at $8.76), decreasing direct ownership by 4% to 73,313 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/18/25 5:40:54 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2025 RBC Capital Markets Global Healthcare Conference, to be held May 20-21, 2025 in New York, NY. 2025 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: May 21, 2025Time: 8:30 a.m. ETWebcast: Click here About CorbusCorbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people def

      5/8/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumorsSAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 inverse agonist CRB-913Dose escalation study on schedule for completion in Q4 2025 for the anti-αvβ8 integrin mAB-CRB-601 in solid tumors NORWOOD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2025. "During the first quarter of 2025, we continu

      5/6/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

      CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the

      3/28/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 7:48:14 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 6:41:20 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 4:05:29 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Corbus Pharma

      William Blair initiated coverage of Corbus Pharma with a rating of Outperform

      2/28/25 7:22:12 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Corbus Pharma

      Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

      12/2/24 9:55:40 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Corbus Pharma with a new price target

      Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00

      7/30/24 6:19:42 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CRBP
    SEC Filings

    See more

    $CRBP
    Leadership Updates

    Live Leadership Updates

    See more
    • Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      9/24/24 4:04:18 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $23,327,560 worth of shares (550,000 units at $42.41) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/11/24 5:34:06 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $14,250,000 worth of shares (750,000 units at $19.00) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/6/24 4:00:46 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Corbus Pharmaceuticals Holdings Inc.

      10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 4:21:10 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 8:30:09 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.

      DEFA14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      4/1/25 4:36:19 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

      NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e

      8/20/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

      NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h

      2/28/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

      NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors. "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Our recent license agreement for CRB-701 has helped cement our position as a precision o

      3/6/23 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care